eftilagimod alpha,pembrolizumab
immutep,merck
['pembro', 'lcsm,(-blcsm)', 'nsclc', 'tacti-002', 'sclc', 'immutep']
 's tacti-002 met its primary objective for 1st nsclc patients in a pd-l1 all-comer trial. data presented at #asco22 by dr efti + pembro - orr of 38.6%
encouraging responses in all pd-l1 status groups
#lcsm #immune2cancer 
The global leader in developing LAG-3 therapeutics (ASX: IMM, NASDAQ: IMMP)